← Back to Search

Treatment with PD1/L1 monotherapy for Non-Small Cell Lung Cancer

N/A
Recruiting
Led By Misako Nagasaka, MD,PhD
Research Sponsored by University of California, Irvine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Study Summary

This is a pilot study collecting data on the diversity and composition of gut microbiomes in subjects with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) while receiving treatment for NSCLC.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Gut microbiomes in advanced/metastatic NSCLC patients
Secondary outcome measures
Change in microbiome diversity and composition from baseline (prior to start of therapy) to first post-treatment evaluation scan.
Clinical Response Rate (RR)
Overall survival (OS)
+1 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: Treatment with Tyrosine Kinase InhibitorExperimental Treatment1 Intervention
Group II: Treatment with PD1/L1 monotherapyExperimental Treatment1 Intervention
Group III: Treatment with PD1/L1 + chemotherapyExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Microbiome
2015
N/A
~130

Find a Location

Who is running the clinical trial?

University of California, IrvineLead Sponsor
544 Previous Clinical Trials
1,922,961 Total Patients Enrolled
Misako Nagasaka, MD,PhDPrincipal InvestigatorChao Family Comprehensive Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects
Misako Nagasaka 2024. "Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06221800.
All > Paid Studies San Diego
~55 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top